首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Efficacy of salbutamol and ipratropium bromide in the management of acute bronchiolitis--a clinical trial.
【24h】

Efficacy of salbutamol and ipratropium bromide in the management of acute bronchiolitis--a clinical trial.

机译:沙丁胺醇和异丙托溴铵在治疗急性细支气管炎中的功效-临床试验。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: A wide range of drugs are commonly used to treat bronchiolitis, but evidence of their effectiveness is limited. OBJECTIVES: To investigate the efficacy of ipratropium bromide and salbutamol in the treatment of patients with moderate-severe bronchiolitis. METHODS: Sixty-nine infants with moderate-severe bronchiolitis hospitalized at their first episode of wheezing or crepitations in the chest were enrolled in a prospective, double-blind, placebo-controlled trial. Patients were randomly assigned to receive nebulized salbutamol, ipratropium bromide or placebo. Main outcome measures were changes in oxygen saturation rates and clinical scores and duration of hospitalization. RESULTS: In the bronchodilator groups, clinical scores were better compared to the placebo group at 30 min (8.4 +/- 1.3 vs. 7.5 +/- 0.8, p < 0.05). Bronchodilator groups had also significantly lower clinical scores (7.3 +/- 1.2 vs. 5.9 +/- 1.1, p < 0.0001, and 5.3 +/- 1.4 vs. 4.5 +/- 1.6, p = 0.006, respectively) and higher oxygen saturation rates compared to the placebo group at 8 and 24 h (89.6 +/- 2.4 vs. 94.3 +/- 4.4, and 92.2 +/- 2.6 vs. 95.9 +/-4.4, respectively, p < 0.0001). Improvement rates and duration of hospitalization were not statistically different among groups. CONCLUSIONS: Clinical scores and oxygen saturation levels improved more rapidly in the bronchodilator groups than in the placebo group up to 24 h, but these drugs did not have a sufficient effect to change the natural course of the disease.
机译:背景:广泛用于治疗毛细支气管炎的药物,但其有效性的证据有限。目的:探讨异丙托溴铵和沙丁胺醇治疗中重度细支气管炎的疗效。方法:将69例初发喘息或胸闷住院的中重度毛细支气管炎婴儿纳入一项前瞻性,双盲,安慰剂对照试验。患者被随机分配接受雾化的沙丁胺醇,异丙托溴铵或安慰剂。主要结局指标是血氧饱和度,临床评分和住院时间的变化。结果:在30分钟时,支气管扩张剂组的临床评分优于安慰剂组(8.4 +/- 1.3 vs. 7.5 +/- 0.8,p <0.05)。支气管扩张剂组的临床评分也显着降低(分别为7.3 +/- 1.2与5.9 +/- 1.1,p <0.0001和5.3 +/- 1.4与4.5 +/- 1.6,p = 0.006)和较高的氧饱和度与安慰剂组相比,在8小时和24小时时的使用率(分别为89.6 +/- 2.4和94.3 +/- 4.4和92.2 +/- 2.6和95.9 +/- 4.4,p <0.0001)。各组之间的改善率和住院时间无统计学差异。结论:在24小时内,支气管扩张剂组的临床评分和血氧饱和度水平比安慰剂组改善得更快,但是这些药物对改变疾病的自然病程没有足够的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号